PreprintArticleVersion 1This version is not peer-reviewed
Screening and Network Pharmacological Analysis of Korean National Insurance‐Covered Herbal Prescriptions with Therapeutic Potential for Mitigating Inflammation in Respiratory Tracts
Version 1
: Received: 5 August 2024 / Approved: 5 August 2024 / Online: 5 August 2024 (16:49:08 CEST)
How to cite:
Yu, G.-R.; Lim, D.-W.; Park, W.-H. Screening and Network Pharmacological Analysis of Korean National Insurance‐Covered Herbal Prescriptions with Therapeutic Potential for Mitigating Inflammation in Respiratory Tracts. Preprints2024, 2024080306. https://doi.org/10.20944/preprints202408.0306.v1
Yu, G.-R.; Lim, D.-W.; Park, W.-H. Screening and Network Pharmacological Analysis of Korean National Insurance‐Covered Herbal Prescriptions with Therapeutic Potential for Mitigating Inflammation in Respiratory Tracts. Preprints 2024, 2024080306. https://doi.org/10.20944/preprints202408.0306.v1
Yu, G.-R.; Lim, D.-W.; Park, W.-H. Screening and Network Pharmacological Analysis of Korean National Insurance‐Covered Herbal Prescriptions with Therapeutic Potential for Mitigating Inflammation in Respiratory Tracts. Preprints2024, 2024080306. https://doi.org/10.20944/preprints202408.0306.v1
APA Style
Yu, G. R., Lim, D. W., & Park, W. H. (2024). Screening and Network Pharmacological Analysis of Korean National Insurance‐Covered Herbal Prescriptions with Therapeutic Potential for Mitigating Inflammation in Respiratory Tracts. Preprints. https://doi.org/10.20944/preprints202408.0306.v1
Chicago/Turabian Style
Yu, G., Dong-Woo Lim and Won-Hwan Park. 2024 "Screening and Network Pharmacological Analysis of Korean National Insurance‐Covered Herbal Prescriptions with Therapeutic Potential for Mitigating Inflammation in Respiratory Tracts" Preprints. https://doi.org/10.20944/preprints202408.0306.v1
Abstract
Long COVID is a persistent symptom that appears in many COVID-19 patients, regardless of whether they are asymptomatic, mild, or severe. At least 10% worldwide are suffering from long COVID. The anti-inflammatory effect was evaluated in LPS-treated RAW264.7 cells using six Korean national insurance-covered herbal prescriptions with therapeutic potential for mitigating inflammation in the respiratory tract, and additional network pharmacology analysis was performed. Soshihotang (SST) significantly downregulated iNOS and COX2 expression, reduced the production of NO (nitric oxide) and inflammatory cytokines, such as TNFα, IL-1β, and IL-6, and inhibited IκBα phosphorylation and reduced the nuclear translocation of NF-κB in LPS-treated RAW264.7 cells. Network pharmacological analysis showed that SST was closely related to the NF-κB signaling pathway. Further study on the potential of herbal prescriptions will be needed before they can be used clinically by long COVID patients.
Medicine and Pharmacology, Medicine and Pharmacology
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
